公开(公告)号：EP2488199A1

公开(公告)日：2012-08-22

申请号：EP10775965.6

申请日：2010-10-14

申请人： Merrimack Pharmaceuticals, Inc. ,  Dyax Corp.

发明人： SCHOEBERL, Birgit ,  NIELSEN, Ulrik ,  KUDLA, Arthur, J. ,  MURUGANANDAM, Arumugam ,  BUCKLER, David ,  LUGOVSKOY, Alexey, Alexandrovich ,  FITZGERALD, Jonathan, Basil ,  XU, Lihui ,  KOHLI, Neeraj

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K14/525 ,  C07K14/765 ,  C07K16/28 ,  C07K16/32 ,  C07K16/46 ,  C07K19/00

CPC分类号： C07K16/2863 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/31 ,  C07K2319/70

摘要： Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways.

公开(公告)号：EP2861210A1

公开(公告)日：2015-04-22

申请号：EP13731230.2

申请日：2013-06-12

申请人： Merrimack Pharmaceuticals, Inc.

发明人： BAYEVER, Eliel ,  DHINDSA, Navreet ,  FITZGERALD, Jonathan, Basil ,  LAIVINS, Peter ,  MOYO, Victor ,  NIYIKIZA, Clet

IPC分类号： A61K9/00 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/517 ,  A61P35/00

CPC分类号： A61K31/4745 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/1271 ,  A61K31/513 ,  A61K31/517 ,  A61K31/519 ,  A61K31/573 ,  A61K45/06 ,  A61K2300/00

摘要： Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

摘要翻译： 提供了通过单独施用脂质体伊立替康（MM-398）或与另外的治疗剂组合来治疗患者胰腺癌的方法。 在一个实施方案中，脂质体伊立替康（MM-398）与5-氟尿嘧啶和甲酰四氢叶酸共同施用。

公开(公告)号：EP2318548A2

公开(公告)日：2011-05-11

申请号：EP09791584.7

申请日：2009-08-17

申请人： Merrimack Pharmaceuticals, Inc.

发明人： SCHOEBERL, Birgit ,  HARMS, Brian ,  GIBBONS, Francis, David ,  FITZGERALD, Jonathan, Basil ,  ONSUM, Matthew, David ,  NIELSEN, Ulrik ,  KUBASEK, William

IPC分类号： C12Q1/68 ,  C07K16/32

CPC分类号： G01N33/6893 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/31 ,  C12Q1/6809

摘要： The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.

公开(公告)号：EP2318548B1

公开(公告)日：2013-10-16

申请号：EP09791584.7

申请日：2009-08-17

申请人： Merrimack Pharmaceuticals, Inc.

发明人： SCHOEBERL, Birgit ,  HARMS, Brian ,  GIBBONS, Francis, David ,  FITZGERALD, Jonathan, Basil ,  ONSUM, Matthew, David ,  NIELSEN, Ulrik ,  KUBASEK, William

IPC分类号： C12Q1/68 ,  C07K16/32

CPC分类号： G01N33/6893 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/31 ,  C12Q1/6809

公开(公告)号：EP2699602B1

公开(公告)日：2017-03-01

申请号：EP12773950.6

申请日：2012-04-19

申请人： Merrimack Pharmaceuticals, Inc.

发明人： BAUM, Jason ,  JOHNSON, Bryan ,  LUGOVSKOY, Alexey, Alexandrovich ,  XU, Lihui ,  KOHLI, Neeraj ,  FITZGERALD, Jonathan, Basil ,  ADAMS, Sharlene

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K16/2869 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Provided herein are novel antiErbB3 and anti-IGF-IR antibodies (e.g., monoclonal antibodies). Also provided herein are novel monospecific and bispecific antibodies that are useful as anti neoplastic agents and that bind specifically to human IGF-IR and/or human ErbB3. Exemplary antibodies inhibit signal transduction through both or either of IGF-IR and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-IR binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region.

摘要翻译： 提供可用作抗肿瘤剂并且特异性结合人IGF-1R和人ErbB3的单特异性和双特异性抗体。 示例性抗体通过IGF-1R和ErbB3之一或两者抑制信号转导。 示例性的多价蛋白质包含至少一个抗IGF-1R结合位点和至少一个抗ErbB3结合位点。 在某些实施方案中，结合位点可以通过免疫球蛋白恒定区连接。 还提供了抗ErbB3和抗IGF-1R抗体（例如，单克隆抗体）。

公开(公告)号：EP2699602A2

公开(公告)日：2014-02-26

申请号：EP12773950.6

申请日：2012-04-19

申请人： Merrimack Pharmaceuticals, Inc.

发明人： BAUM, Jason ,  JOHNSON, Bryan ,  LUGOVSKOY, Alexey, Alexandrovich ,  XU, Lihui ,  KOHLI, Neeraj ,  FITZGERALD, Jonathan, Basil ,  ADAMS, Sharlene

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  C07H21/04

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K16/2869 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Provided herein are novel antiErbB3 and anti-IGF-IR antibodies (e.g., monoclonal antibodies). Also provided herein are novel monospecific and bispecific antibodies that are useful as anti neoplastic agents and that bind specifically to human IGF-IR and/or human ErbB3. Exemplary antibodies inhibit signal transduction through both or either of IGF-IR and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-IR binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region.